Aveo Oncology reports results of exploratory Phase 2 study of ficlatuzumab

October 1, 2012

AVEO Oncology announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer were presented at the 2012 Congress of the European Society for Medical Oncology. As previously reported, the study did not achieve its primary endpoint; however, the results presented at ESMO suggest that the addition of ficlatuzumab to gefitinib may be effective in select subsets of patients.